IPG Photonics Corporation (IPGP) | The Buildout — AI Infrastructure
The Verdict
IPG Photonics makes fiber lasers, laser amplifiers, diodes and complete laser systems. Its lasers cut, weld, clean and mark metal for industrial customers, and its components sit inside medical devices, defense systems and the tools that make semiconductors. For the AI buildout the link is indirect: IPG sells lasers to the equipment makers that serve chip fabs, and its welding lasers are specified into batteries used for data-center-backed stationary storage. It is not a data-center optics company — its fiber expertise is in delivering laser power, not moving data.
| Market Cap | — |
| Revenue (TTM) | $1.1B |
| Revenue Growth | +13.1% |
| EBITDA Margin (TTM) | 8.5% |
| Net Cash | $855M |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- Q1 FY2026 revenue of $265.5M beat the high end of the $235–265M guide and rose 16.6% y/y — a second consecutive quarter of double-digit growth.
- Q2 FY2026 revenue came in at $278.6M, up 4.9% sequentially, with gross margin of 40.4% versus 37.5% in Q1.
- Management reported book-to-bill 'firmly above 1' for a second consecutive quarter, with strength in North America and Asia.
- The balance sheet held $871M of cash and short-term investments at 2026-06-30 against $16.3M of total debt; the €300M Lumibird Medical deal is funded from cash on hand.
- Systems revenue grew 28.2% y/y in Q1 to $51.8M — 19.5% of sales — as the mix moves toward complete systems rather than components.
What We’re Watching
- Adjusted gross margin was 37.8% in Q1 FY2026, below the mid-40s target; management called it 'a little light given the level of revenue.'
- Tariffs cost roughly 150–160 basis points of gross margin and are guided to persist in 2026; underabsorbed factory expenses are a second, unquantified drag.
- Advanced Solutions, the 14%-of-Q1-revenue growth bucket, declined 4.7% y/y, with defense and micromachining both down.
- The top five customers were 20% of Q1 FY2026 net sales, up from 16% in FY2025 and 13% in FY2024, and IPG says it generally has no fixed-volume purchase agreements.
Demand is strengthening while the margin story is still unresolved. Revenue has run ahead of plan, bookings have stayed above shipments, and the balance sheet is strong enough to fund the €300M Lumibird Medical deal from cash. But gross margin is only recovering off a low base, and management itself flagged tougher second-half 2026 comparisons against a strong prior-year period. The open question is whether margin closes toward the mid-40s target before that comparison bites — and whether the small semiconductor and storage-battery AI lines ever get large enough to be reported on their own.
Earnings Beat
IPG reported second-quarter 2026 revenue of $278.6M, up 4.9% from the $265.5M reported in Q1 FY2026. Gross margin came in at 40.4%, up from 37.5% in the prior quarter. The company's 2026-08-04 release credited improving industrial demand and continued work on costs and gross margin. Segment detail and call commentary for the quarter were not in the material.
| Metric | Q2 FY2026 | Q1 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $279M | $266M | $251M | +11.1% |
| Gross margin | 40.4% | 37.5% | 37.3% | +310bps |
| EBITDA | $36M | $8M | $16M | +125.8% |
| EPS | $0.12 | $0.04 | $0.15 | −21.8% |
Total bookings were strong in the quarter with book-to-bill firmly above 1 for the second consecutive quarter.— Mark Gitin, CEO, 2026-05-05
Management tone: The most recent call on record is the Q1 FY2026 call of 2026-05-05. Management was confident on demand and direct about margins: it flagged a stronger-than-expected quarter and bookings above shipments for a second quarter, while acknowledging that gross margin was 'a little light given the level of revenue' and that tariffs and underabsorbed factory costs would persist. Executives held the mid-40s gross-margin target and named tariffs as the main headwind, and they declined to break out bookings by the two new reporting buckets.
Management Guidance
Management's most recent guidance, issued with the Q1 FY2026 results for the second quarter of 2026, was revenue of $260–290M, adjusted gross margin of 37%–40% (including about 150 basis points of ongoing tariff impact), adjusted operating expenses of $92–95M, adjusted earnings per diluted share of $0.25–$0.55 on roughly 43 million diluted shares, and adjusted EBITDA of $32–48M. The guidance assumed exchange rates of euro 0.87, Japanese yen 159 and Chinese yuan 6.92, and management said adjusted operating expenses would rise moderately through the year to support growth initiatives.
Trajectory
Revenue has moved from $251M in the quarter ended September 2025 to $279M in the quarter ended June 2026, a stable range with one down-quarter in between. The mix is shifting toward complete systems, which grew 28.2% y/y in Q1 FY2026 against 14.0% for lasers and components. Gross margin has held in the high 30s to low 40s — 37.5% in Q1 and 40.4% in Q2. Management attributes the revenue line to an industrial recovery plus battery orders; roughly 150 basis points of tariffs and underabsorbed factory costs are holding margin back.
The Model
The model projects FY+1 revenue of $1,118M with EBITDA of $176M (15.7% margin), and FY+2 revenue of $1,253M with EBITDA of $218M (17.4% margin). The near-term anchor is the industrial recovery and battery-driven demand plus the latest quarter's gross-margin improvement; the FY+2 step assumes the margin gap to the mid-40s target narrows as factory absorption improves and the mix keeps shifting toward systems.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $1.0B | $1.1B | $1.3B |
| YoY Growth | — | +11.4% | +12.1% |
| EBITDA | $80M | $176M | $218M |
| EBITDA Margin | 8.0% | 15.7% | 17.4% |
Projections are the median of 5 independent model runs. The model’s revenue sits 3.1% above analyst consensus.
Management's most recent guidance, issued with the Q1 FY2026 results for the second quarter of 2026, was revenue of $260–290M, adjusted gross margin of 37%–40% (including about 150 basis points of ongoing tariff impact), adjusted operating expenses of $92–95M, adjusted earnings per diluted share of $0.25–$0.55 on roughly 43 million diluted shares, and adjusted EBITDA of $32–48M. The guidance assumed exchange rates of euro 0.87, Japanese yen 159 and Chinese yuan 6.92, and management said adjusted operating expenses would rise moderately through the year to support growth initiatives.
What Could Go Right — and Wrong
- Industrial demand holds through the second-half 2026 comparison and book-to-bill stays above shipments, turning the recovery into expansion.
- Semiconductor becomes a disclosed, growing line — the cleanest test of the AI-linked demand management says is 'starting to make impact.'
- Crossbow converts into multiple orders from multiple customers, lifting defense beyond a single $10M Lockheed Martin order.
- The German fiber facility starts up, reversing the underabsorption drag and moving adjusted gross margin toward the mid-40s target.
- Lumibird Medical closes in the fourth quarter of 2026 and adds an owned medical business alongside the 2026 medical backlog.
- The second-half comparison bites and the book-to-bill streak ends, exposing the industrial recovery as cyclical.
- Advanced Solutions keeps declining — the 14%-of-revenue bucket fell 4.7% y/y even as management built its growth story around it.
- Rising customer concentration proves to be dependence; the top five were 20% of Q1 net sales with no fixed-volume agreements behind them.
- A single-site manufacturing disruption, since the 10-K says IPG has no redundant production lines for some components such as diodes.
- Tariffs and underabsorption persist, and the mid-40s gross-margin target stays out of reach.
Looking Ahead
The next twelve months turn on three things the company has put on the record: whether industrial demand holds through the tougher second-half 2026 comparison, whether gross margin keeps closing toward the mid-40s target as tariffs and factory absorption move, and whether the Lumibird Medical acquisition closes in the fourth quarter of 2026 after French and AMF approvals. The semiconductor and storage-battery lines are the AI-adjacent pieces to watch for scale; neither is broken out today.
- Q2 2026Crossbow follow-on shipments — Lockheed Martin's $10M order ships over multiple quarters.
- Q4 2026Lumibird Medical close — Subject to French FDI authorization and an AMF waiver.
- 2026German fiber facility CapEx — Part of the $90–100M 2026 budget; Q1 spend was $16M.
- Full-year 2026Medical backlog delivery — Management points to a very strong 2026 medical backlog.
- 2026 and 2027Medical product approvals — New medical approvals and introductions expected; products unnamed.
- 2026–2027Lumibird earn-out metrics — Up to €50M contingent on 2026 and 2027 performance.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $977M | $1.0B | $1.1B | +2.7% |
| Gross Margin | 34.5% | 38.1% | 38.4% | +362bps |
| EBITDA | −$147M | $80M | $91M | +154.5% |
| EBITDA Margin | -15.0% | 8.0% | 8.5% | +2,300bps |
| Net Income | −$182M | $31M | $28M | +117.2% |
| Free Cash Flow | $149M | −$4M | $21M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)38.4%
- EBITDA Margin (TTM)8.5%
- Net Margin (TTM)2.6%
- ROIC0.5%
- FCF Conversion22.9%
- SBC / Revenue-1.1%
The Company
IPG Photonics develops, manufactures and sells high-performance fiber lasers, fiber amplifiers, diode lasers and laser-based systems. Its lasers cut, weld, clean and mark metal for industrial customers, and its lasers and components go into medical devices, defense systems and the tools that make semiconductors. It sells to original equipment makers, system integrators and end users worldwide.
The company is vertically integrated: it designs and makes most of the key components inside its finished products, including semiconductor diodes and specialty optical fibers. Its main plants are in Burbach, Germany (586,800 square feet, optical fiber and final assembly), Oxford, Massachusetts (550,300 square feet, diodes) and Marlborough, Massachusetts (402,800 square feet), with systems integration in Davenport, Iowa. Vertical integration is also why a component problem at one site can reach a customer's system — the 10-K says some components, such as diodes, are made at a single facility with no redundant lines.
Business Segments
Competitive Landscape
Fiber lasers are a contested market with large competitors, including several cost-competitive Asian suppliers. IPG's 10-K names Coherent, JPT Opto-Electronics, Laserline, Lumentum, MKS Instruments, nLight, Trumpf and Wuhan Raycus. The company's own language — 'displacing incumbent technologies,' 'outperforming the market' — describes a contest rather than a protected position. One product family management calls a differentiator, adjustable-mode-beam lasers for battery welding, was ruled in the UPC courts to infringe two Trumpf patents and settled for a $13.5M payment plus a royalty-bearing worldwide license.
- Trumpf GmbH + Co. KGNamed in the 10-K; IPG settled worldwide patent litigation with it for a $13.5M payment and a royalty-bearing license.
- Named in the 10-K; also cited as an alternative supplier semiconductor equipment makers could requalify if IPG lasers became unavailable.
- nLight, Inc.Named in the 10-K; cited as an alternative supplier, and described in read-throughs as exiting legacy cutting and welding.
- Named in filings; not otherwise discussed.
- MKS Instruments, Inc.Named in filings; not otherwise discussed.
Supply Chain
IPG is a vertically integrated laser maker rather than a link in someone else's chain — it builds most of its own components. No neighbor read-through named IPG, so its AI link runs through chip-equipment makers and battery factories.